EZH2 and neoplasm: Another multi-omics-related study concluded that expression of enhancer of zeste homolog 2 (EZH2), which is associated with DNA methylation modifications, tumor mutation burden, tumor neoantigen burden, mismatch repair, tumor microenvironment, and genes related to the immune system, served as an independent predictor of prognosis and immune response in PC patients [147].